Caris Life Sciences, Inc. (CAI) Stock Forecast
CAI analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.36 / 5 from 14 analysts
- Price target
- $31.62 average of analyst targets
- Upside to target
- +3.5% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.03
- 52-week range
- $14.55 – $32.27
CAI analyst ratings
14 analystsNumber of analysts at each rating.
CAI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CAI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.02 | −$0.01 | $0.07 | $0.08 | −74.9% | 10 |
| Current fiscal year (2026) | $0.14 | $0.04 | $0.26 | −$0.41 | +133.9% | 11 |
| Next fiscal year (2027) | $0.37 | $0.05 | $0.52 | $0.14 | +169.5% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CAI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $254.7M | $242.7M | $263.0M | +17.4% | 13 |
| Current fiscal year (2026) | $1.03B | $1.00B | $1.03B | +26.8% | 14 |
| Next fiscal year (2027) | $1.23B | $1.17B | $1.29B | +19.3% | 14 |
CAI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CAI revenue: reported and forecast
CAI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.04 | $0.03 | $0.03 | $0.02 | $0.02 | −50.1% | 3 up · 6 down |
| Current fiscal year (2026) | $0.13 | $0.14 | $0.14 | $0.14 | $0.14 | +6.2% | 0 up · 2 down |
| Next fiscal year (2027) | $0.36 | $0.38 | $0.38 | $0.37 | $0.37 | +4.6% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CAI earnings surprises
Reported EPS vs the consensus estimate for the last 6 quarters; CAI beat in 3 of 6.
What analysts expect from CAI
14 analysts cover Caris Life Sciences; their consensus rating is buy (4.36 on a 1–5 scale, where 5 is a strong buy). The average price target is $31.62, 3.5% above the latest close of $30.56. Analysts expect earnings of $0.14 per share for 2026, +133.9% from a year earlier. For 2027 the average estimate is $0.37 per share on revenue of $1.2 billion. Caris Life Sciences beat the EPS estimate in 3 of the last 6 quarters.
Related: CAI income statement, CAI key metrics, CAI chart. See the CAI stock overview for the latest quote and news.
CAI forecast FAQ
What is Caris Life Sciences's price target?
The average analyst price target for Caris Life Sciences is $31.62, 3.5% above the latest close of $30.56.
Is Caris Life Sciences a buy, hold or sell?
Of 14 analysts covering Caris Life Sciences, 9 rate it a strong buy, 1 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Caris Life Sciences's EPS forecast?
Analysts forecast $0.14 per share for 2026 (range $0.04 to $0.26); for 2027 the estimate is $0.37.
What is Caris Life Sciences's revenue forecast?
The average revenue estimate for 2026 is $1.0 billion, growth of 26.8%; for 2027 it is $1.2 billion.
When does Caris Life Sciences report earnings?
Caris Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $0.03.
Does Caris Life Sciences usually beat earnings estimates?
Caris Life Sciences reported EPS at or above the analyst estimate in 3 of the last 6 quarters.